People: Valeant Pharmaceuticals International Inc (VRX.N)

VRX.N on New York Stock Exchange

117.26USD
22 Aug 2014
Price Change (% chg)

$3.45 (+3.03%)
Prev Close
$113.81
Open
$112.82
Day's High
$117.74
Day's Low
$112.82
Volume
290,112
Avg. Vol
420,941
52-wk High
$152.92
52-wk Low
$95.28

Search Stocks

Summary

Name Age Since Current Position

J. Michael Pearson

53 2011 Chairman of the Board, Chief Executive Officer

Bhaskar Chaudhuri

59 2009 President

Howard Schiller

2012 Chief Financial Officer, Executive Vice President, Director

Peter Blott

50 2007 Chief Financial Officer, Executive Vice President

Elisa Karlson

53 2008 Executive Vice President, Chief Administrative Officer

Robert Chai-Onn

42 2012 Executive Vice President, General Counsel, Corporate Secretary and Corporate Business Development

Steve Min

50 2008 Executive Vice President, General Counsel, Corporate Secretary

Ari Kellen

2014 Executive Vice President, Company Group Chairman

Laizer Kornwasser

2013 Executive Vice President, Company Group Chairman

Martin Mercer

Executive VP, International

Brian Stolz

37 2011 Executive Vice President - Administration, Chief Human Capital Officer

Ryan Weldon

35 2012 Executive Vice President, Company Group Chairman

Geoffrey Glass

40 Senior VP & CIO

Susan Hall

53 2012 Senior Vice President, Global Head - Research and Development

Robert Ingram

71 2011 Lead Independent Director

Brandon Boze

32 2009 Director

Fred Hassan

68 2013 Director

Richard Koppes

65 2002 Director

Lawrence Kugelman

70 2002 Director

Anders Lonner

66 2009 Director

Stephen Stefano

56 2009 Director

Ronald Farmer

63 2011 Independent Director

Theo Melas-Kyriazi

2010 Independent Director

Robert Power

56 2008 Independent Director

Norma Provencio

56 2010 Independent Director

Lloyd Segal

49 2007 Independent Director

Katharine Stevenson

51 2010 Independent Director

Laurie Little

Vice President - Investor Relations

Biographies

Name Description

J. Michael Pearson

Mr. J. Michael Pearson is Chairman of the Board, Chief Executive Officer of Valeant Pharmaceuticals International Inc. Mr. Pearson has been the CEO of the Company and serving on the Board since September 2010 and the Chairman of the Board since March 2011. From February 2008 to September 2010, he was the chairman of the board and CEO of VPI before the Merger. Prior to that, Mr. Pearson served on McKinsey’s board of directors until he left to join VPI. He joined McKinsey in 1984, and over a 23-year career, he worked with CEOs and was an integral driver of turnarounds, acquisitions, and corporate strategy. Within McKinsey, Mr. Pearson held various positions, including head of its global pharmaceutical practice and head of its mid-Atlantic region.

Bhaskar Chaudhuri

Dr. Bhaskar Chaudhuri, Ph.D., is President of Valeant Pharmaceuticals International. since March 2009. Prior to joining Valeant upon the Company’s acquisition of Dow Pharmaceutical Sciences, Inc. (“Dow”) on December 31, 2008, Dr. Chaudhuri served for seven years as Dow’s President and Chief Executive Officer and a member of Dow’s Board of Directors. Before joining Dow, Dr. Chaudhuri served as Executive Vice President of Scientific Affairs at Bertek Pharmaceuticals (“Bertek”), a subsidiary of Mylan Laboratories (“Mylan”), where he oversaw the R & D activities for its Cardiovascular, Neurology and Dermatology businesses, as well as a segment of its manufacturing operations. Prior to his positions at Bertek, Dr. Chaudhuri served as the General Manager of the Dermatology Division of Mylan. Dr. Chaudhuri joined Mylan through the acquisition of Penederm Inc., where he held multiple positions from 1992 to 1998, and became the Vice President of R & D in 1997.

Howard Schiller

Mr. Howard Bradley Schiller is Chief Financial Officer, Executive Vice President, Director of Valeant Pharmaceuticals International Inc. Mr. Schiller been the Chief Financial Officer (“CFO”) of the Company since December 2011 and has been serving on the Board of the Company since September 2012. Mr. Schiller joined the Company following a 24-year career at Goldman Sachs, a global investment banking firm. From 2009 to 2010, Mr. Schiller was the chief operating officer for the Investment Banking Division of Goldman Sachs, responsible for the management and strategy of the business. From 2003 to 2009, he was responsible for the global healthcare, consumer products, retail, industrial and natural resource businesses in the Investment Banking Division of Goldman Sachs. During his 24 years at Goldman Sachs, he advised multinational companies on strategic transactions, financings, restructuring and leveraged buyouts.

Peter Blott

Mr. Peter J. Blott is Executive Vice President and Chief Financial Officer of Valeant Pharmaceutical International. since March 2007. He served as Senior Vice President, Group Financial Controller from March 2004 to March 2007. Prior to that, he served asVice President, Operations Finance from July 2003 to February 2004. With 20 years of finance and accounting experience, Mr. Blott has an background in accounting and operations in the pharmaceutical industry. From January 2002 to June 2003, Mr. Blott served as Head of Finance and Logistics for Otsuka Pharmaceuticals Europe. Prior to that he worked for over ten years at GlaxoSmithKline (formerly Glaxo Wellcome), where he held a number of management and financial positions within various manufacturing, commercial and head office operations. Mr. Blott is a U.K. Chartered Accountant, qualifying with Coopers & Lybrand in London, England.

Elisa Karlson

Ms. Elisa A. Karlson is Executive Vice President and Chief Administrative Officer of Valeant Pharmaceuticals International since April 2008. Prior to that, she spent ten years at McKinsey as Director of Personnel Management and Finance where she led staffing and professional development, human resources, recruiting, finance and accounting, and information technology. Earlier in her career, she spent over 15 years in IT where she designed and developed mortgage-backed securities and investment banking applications at Chemical Bank and Morgan Stanley and moved into strategic IT consulting at the Information Consulting Group, which became part of McKinsey, and at Kwasha Lipton, which became part of PricewaterhouseCoopers LLP.

Robert Chai-Onn

Mr. Robert Roswell Chai-Onn is Executive Vice President, General Counsel, Corporate Secretary and Corporate Business Development of Valeant Pharmaceuticals International Inc. He has been Executive Vice President, General Counsel and Corporate Secretary since September 2010 and effective March 28, 2012 he became Executive Vice President, General Counsel, Corporate Secretary and Corporate Business Development. From 2004 to September 2010, Mr. Chai-Onn was Vice President, Assistant General Counsel at VPI. He has been instrumental in the Company’s strategic transactions, including the Merger. Prior to 2004, Mr. Chai-Onn was a corporate lawyer at the law firm of Gibson, Dunn & Crutcher LLP, where he performed a variety of corporate, mergers and acquisitions and financial legal work.

Steve Min

Mr. Steve T. Min is Executive Vice President, General Counsel and Corporate Secretary of Valeant Pharmaceuticals International since June 2008. From August 1992 to June 2008, Mr. Min served as Associate General Counsel at McKinsey working in its New York, London and Mid-Atlantic offices. During his tenure at McKinsey, Mr. Min supported a variety of industry and functional practices, including mergers and acquisitions, private equity, business technology and public sector. Mr. Min was a corporate/securities associate at Rubin Baum LLP from February 1990 to August 1992, and at Schulte Roth & Zabel LLP from October 1987 to February 1990.

Ari Kellen

Dr. Ari Kellen has been appointed as Executive Vice President, Company Group Chairman of the Company., with effective January 1, 2014. Dr. Kellen was a senior partner in McKinsey & Company's Mid-Atlantic Office. Since joining McKinsey in March 1991, Ari has led numerous strategy, organization and performance improvement studies for health care companies, including corporate strategies for boards and top management teams, business unit strategies for medical device, pharmaceutical and biotechnology, and health care services clients, and regional and country growth strategies. In addition, Ari developed business model innovation and turnaround strategies as well as top level organization structure, governance and decision-making redesigns. Ari directed performance turnarounds addressing revenue, cost, capital and change management. Ari received a Bachelor of Medicine and Bachelor of Surgery (MBBCh) degree and an MBA degree, both with distinction, from the University of the Witwatersrand in South Africa.

Laizer Kornwasser

Mr. Laizer D. Kornwasser has been appointed as Executive Vice President, Company Group Chairman of Valeant Pharmaceuticals International Inc., effective February 1, 2013. He was a Senior Executive at Medco Health prior to its acquisition by Express Scripts. At Medco he reported directly into the CEO and was a member of Executive Committee. He served as Senior Vice President, Consumer Solutions and Retail Markets and was responsible for retail network and mail pharmacy products and strategy. He oversaw network pricing, negotiations, plan designs and programs that maximized the retail and mail channels. Mr. Kornwasser was also responsible for the integrated care solution for Medco's six million members with diabetes. Mr. Kornwasser joined Medco in August 2003, and was initially responsible for building a business development team, post spin-off from Merck. In this role he oversaw all acquisitions, joint ventures and was actively involved in developing the company's long-term growth strategy. He later assumed responsibility for the companies' channel and generic drug strategy and was President of its diabetes division, which focused on direct to consumer solutions. Prior to joining Medco, Mr. Kornwasser held positions at Merrill Lynch and Coopers & Lybrand, and served as an associate professor at Yeshiva University. He has an MBA from Harvard Business School and a BS in Accounting from Yeshiva University.

Martin Mercer

Martin Mercer was appointed Executive Vice President, Latin America Operations for Valeant Pharmaceuticals International in November 2003. Mr. Mercer's broad management background includes market development, competitive positioning and new product launches for pharmaceutical companies in Latin America. Prior to joining Valeant, Mr. Mercer was Managing Director for GlaxoWellcome, Venezuela where he led the company to a 28 percent per annum growth; more recently as Vice President for GlaxoSmithKline North Andes Zone in Colombia and Venezuela he expanded the company presence in both countries. Mr. Mercer had been with GlaxoSmithKline for over twenty years, holding positions of increasing responsibility in marketing, sales, managing director and Regional Vice President. Mr. Mercer was born and educated in Buenos Aires and is based in Mexico City, headquarters of Valeant's Latin American Operations.

Brian Stolz

Mr. Brian M. Stolz is Executive Vice President - Administration, Chief Human Capital Officer of Valeant Pharmaceuticals International, Inc., since June 2011. Prior to joining the Company, from February 2009 through June 2011, Mr. Stolz was a Principal at ghSMART, a leadership consulting and advisory firm where he worked with corporate and alternative investment clients on human resource issues. In this role, he assessed and trained C-Level executives and professionals, created and implemented hiring and performance evaluation processes and advised boards and investment committees on senior-level hires. Prior to joining ghSMART, from November 2007 to December 2008, Mr. Stolz was a consultant at McKinsey and was a member of the McKinsey Pharmaceuticals and Medical Products group.

Ryan Weldon

Mr. Ryan Weldon has been Executive Vice President, Company Group Chairman of Valeant Pharmaceuticals International Inc., since December 2012. He served as Vice President & General Manager, Aesthetics from December 2011 to December 2012 and Vice President & General Manager, Neurology & Other from January 2010 to December 2011. He joined VPI in September 2008 and had held roles of Senior Director, Neurology and Director, Epilepsy at VPI.

Geoffrey Glass

Mr. Geoffrey M. Glass is the Executive Vice President Sales and Marketing at Patheon, Inc. Previously, he spent almost five years on the Executive Team at Valeant Pharmaceuticals. He was the Senior Vice President of Asian Operations at Valeant Pharmaceuticals. Prior to leading the Asian business for Valeant, he was Senior Vice President and Chief Information Officer of Valeant Pharmaceuticals International. Prior to joining Valeant, he was the Global Leader of Life Sciences Operations Excellence Practice for Cap Gemini. Mr. Glass holds a Bachelor of Arts in Economics and Political Science at the University of Arizona.

Susan Hall

Dr. Susan T. Hall is Senior Vice President, Global Head - Research and Development of Valeant Pharmaceuticals International, Inc., since February 2012. Before joining VPI in 2006 as Vice President, Global Regulatory Science and Compliance, she was with GSK, initially in the U.K. and then in the U.S., where she held various management and leadership positions within the disciplines of Clinical Pharmacology, Project Management, Medical Affairs, Genomics and Regulatory Affairs.

Robert Ingram

Mr. Robert A. Ingram is Lead Independent Director of Valeant Pharmaceuticals International Inc. Mr. Ingram has been serving on the Board of the Company since September 2010, was the Lead Director from September 2010 to December 2010, was the Chairman of the Board from December 2010 to March 2011. Since January 2007, Mr. Ingram has been a general partner at Hatteras Venture Partners, a venture capital firm with a focus on biopharmaceuticals, medical devices, diagnostics and related opportunities in human medicine. Since January 2010, he has served as a special advisor to the Chief Executive Officer (“CEO”) of GlaxoSmithKline (“GSK”). He served as Vice Chairman Pharmaceuticals of GSK from 2002 through 2009 and Chief Operating Officer and President of Pharmaceutical Operations, CEO of Glaxo Wellcome plc from October 1997 to December 2000 and chairman of the board of Glaxo Wellcome Inc., Glaxo Wellcome plc’s U.S. subsidiary, from January 1999 to December 2000. Mr. Ingram was President and CEO of Glaxo Wellcome Inc. from October 1997 to January 1999. Mr. Ingram is also a member of the Board of Advisors for the H. Lee Moffitt Cancer Center and Research Triangle Institute, as well as Chairman of the Board, Research Triangle Foundation of North Carolina and Glaxo North Carolina Foundation. Mr. Ingram currently serves on the boards of Edwards Life Sciences Corporation (member of compensation committee); CREE, Inc. (lead director, member of compensation committee and governance and nominations committee); and Elan Corporation, plc (chairman of the board). He is a former director of Allergan Inc., Misys plc, Nortel Networks Corporation (“Nortel”), Wachovia Corporation, OSI Pharmaceuticals, Inc., Lowe’s Companies, Pharmaceuticals Product Development Inc, and Valeant Pharmaceuticals International (“VPI”), which was merged into the Company, then known as Biovail Corporation, in September 2010 (the “Merger”) at which time the Company changed its name to Valeant Pharmaceuticals International, Inc.

Brandon Boze

Mr. Brandon B. Boze serves as Director of Valeant Pharmaceuticals International. He has been serving on the Board of the Company since December 2009. Since August 2005, Mr. Boze has held the position of Vice President at ValueAct Capital (“ValueAct Capital”). Prior to joining ValueAct Capital, Mr. Boze worked at Lehman Brothers in a variety of positions within merchant banking, utilities investment banking and technology mergers and acquisitions. He has a bachelor’s degree from Vanderbilt University in Engineering and is a CFA charterholder. Mr. Boze serves on the Board, and participates in Finance and Audit Committee meetings as an observer with no voting rights, pursuant to the Standstill and Board Nomination Agreement dated December 17, 2009 (the “Standstill and Board Nomination Agreement”), by and between the Company and ValueAct Capital Master Fund, L.P., VA Partners I, LLC, ValueAct Capital Management, L.P., ValueAct Capital Management, LLC, ValueAct Holdings, L.P. and ValueAct Holdings GP, LLC.

Fred Hassan

Mr. Fred Hassan has been appointed as Director of Valeant Pharmaceuticals International Inc., effective August 7, 2013. Mr. Hassan is the former chairman of the B&L board.

Richard Koppes

Mr. Richard H. Koppes serves as Director of Valeant Pharmaceuticals International. since 2002 and serves as a member of both Compensation Committee and Corporate Governance/Nominating Committee. He is currently a Corporate Governance Fellow at Stanford University School of Law running the Stanford Institutional Investor Forum and Stanford’s Fiduciary College. From 1996 to 2009, he was Of Counsel to the law firm of Jones Day. From May 1986 through July 1996, Mr. Koppes held several positions with the California Public Employees’ Retirement System (CalPERS) including General Counsel, Interim Chief Executive Officer and Deputy Executive Officer. He also founded the National Association of Public Pension Attorneys (NAPPA) and serves as its Administrator, a position he has held for the past eighteen years. He was also on the Board of the Society of Corporate Secretaries and Governance Professionals, and is currently serving on the boards of the Investor Research Responsibility Center Institute (IRRCI), and the National Association of Corporate Directors (NACD). Mr. Koppes is a former director of Apria Healthcare Group Inc. The Board has determined that the deep understanding of complex compensation issues that Mr. Koppes gained through his leadership positions at NAPPA and CalPERS, his knowledge and insight regarding the establishment of corporate governance procedures, his contribution in establishing, maintaining and monitoring standards and policies for ethics, business practices, and compliance that span the Company and his unique perspective based on prior work experience.

Lawrence Kugelman

Mr. Lawrence N. Kugelman serves as Director of Valeant Pharmaceuticals International. since 2002 and serves as a member of both Compensation Committee and Finance and Audit Committee. He is a healthcare consultant and private investor. From December 1995 through October 1996, Mr. Kugelman was President, Chief Executive Officer and Director of Coventry Health Care, Inc., a managed care organization. From 1980 through 1992, he served as a Chief Executive Officer of several HMOs and managed healthcare organizations in the United States. Mr. Kugelman currently serves on the board of Coventry Health Care, Inc. (chairman of Audit Committee) and is a former director of LabOne, Inc. The Board has determined that Mr. Kugelman’s years of managerial experience, which give him the ability to address management issues at the most senior levels and provide critical insight into the operational requirements of a company, and his experience dealing with accounting principles and financial reporting rules and regulations, evaluating financial results and generally overseeing the financial reporting process of a public corporation gained while chairing the audit committee of another public company.

Anders Lonner

Mr. Anders Lonner is Director of Valeant Pharmaceuticals International since 2009. He serves as a member of Compensation Committee. Since 1999, he has been the Group President and Chief Executive Officer of Meda AB. Prior to joining Meda AB, Mr. Lönner served as the Vice President Nordic region of AstraZeneca International and as the Chief Executive Officer of Karo Bio AB. He has a masters degree in business administration from the University of Lund, and has additional management education from Fontaine Bleau Paris. The Board has determined that Mr. Lönner’s experience as the chief executive officer of a public company, where he demonstrated leadership capability and knowledge of complex financial and operational issues facing organizations, his understanding of operations and financial strategy in challenging environments and his insight into international operations and international perspective of industry qualify him to be a member of the Board.

Stephen Stefano

Mr. Stephen F. Stefano is Director of Valeant Pharmaceuticals International. since March 2009 and serves as a member of both Corporate Governance/Nominating Committee and Finance and Audit Committee. He is currently a partner at Synopia Rx, a consulting business for the biotech and pharmaceutical industries. From January 2001 to November 2009, Mr. Stefano was a Senior Vice President of Managed Markets and NeuroHealth Divisions at GlaxoSmithKline plc, a corporation involved in the research, development, manufacturing and sale of pharmaceuticals (“GlaxoSmithKline”). From 1980 to 2001, he held numerous other positions at GlaxoSmithKline. The Board has determined that Mr. Stefano’s deep knowledge of healthcare policy, patient care delivery and managed markets, which provides Board with unique insight and perspective on the priorities of and challenges facing industry, and his operations experience and broad exposure, which allow him to offer specific, practical advice when considering the various issues presented to Board, qualify him to be a member of the Board.

Ronald Farmer

Mr. Ronald Harold Farmer is Independent Director of Valeant Pharmaceuticals International, Inc., since August 2011. Since 2003, Mr. Farmer has been the Managing Director of Mosaic Capital Partners, a Toronto-based holding company with interests in several private companies in Canada and the United States. Mr. Farmer is also Director Emeritus of McKinsey & Company (“McKinsey”) where he spent 25 years in the Toronto and New York offices prior to his retirement in 2003. At McKinsey, he worked with global corporations in a variety of industries on strategy and organization challenges and held a number of leadership positions, including serving as a Managing Partner of the Canadian practice from 1991 to 1997 and its Global eBusiness practice. He served on McKinsey’s Shareholder Council (board of directors). Mr. Farmer is a director on several private company boards including Integran Technologies and PowerMetal Technologies. He has also been a director of the Bank of Montreal since 2003 where he serves on the audit, nominating and governance, and human resources committees. He also serves on the Advisory Council of the Schulich School of Business. He is a former director of Afexa Life Sciences Inc.

Theo Melas-Kyriazi

Mr. Theo Melas-Kyriazi is Independent Director of Valeant Pharmaceuticals International Inc., since September 2010. He has been the Chief Financial Officer of Levitronix Technologies LLC, magnetically levitated bearingless motor technology, since 2011, and served as the Chief Financial Officer of its affiliate, Levitronix LLC since 2006. He was the Chief Financial Officer of Thermo Electron Corporation from January 1999 through October 2004. Mr. Melas-Kyriazi was a Vice President of Thermo Electron Corporation during 1998, in charge of corporate strategy; he served as the CEO of Thermo Spectra Corporation, a publicly-traded majority-owned subsidiary of Thermo Electron, from 1994 to 1998, and was Treasurer of Thermo Electron Corporation and all of its publicly traded subsidiaries from 1988 to 1994. Mr. Melas-Kyriazi is a former director of VPI, Helicos BioSciences Corporation, Cyberkinetics Neurotechnology Systems, Inc. and Glenrose Instruments Inc.

Robert Power

Mr. Robert N. Power is Independent Director of Valeant Pharmaceuticals International Inc., since August 2008. Mr. Power was a faculty member at The Wharton School of Business, University of Pennsylvania, where he taught multinational marketing from 2009 to 2011. Mr. Power has over 25 years’ experience working in the pharmaceutical and biotechnology industry through a number of leadership positions with Wyeth beginning in 1985 through 2007, including Director — New Product Development, Managing Director — U.K./Ireland, Vice President — Global Marketing, President — Europe, Middle East, Africa, President — International and Executive Vice President — Global Business Operations. Mr. Power also has completed the Director Professionalism course offered by the National Association of Corporate Directors.

Norma Provencio

Ms. Norma A. Provencio is Independent Director of Valeant Pharmaceuticals International Inc., since September 2010. She has been president and owner of Provencio Advisory Services, Inc., a healthcare financial and operational consulting firm, since October 2003. From May 2002 to September 2003, she was Partner-in-Charge of the Healthcare Industry for the Pacific Southwest for KPMG LLP. From 1979 to May 2002, she was with Arthur Andersen, and was Partner-in-Charge of Arthur Andersen’s Pharmaceutical, Biomedical and Healthcare Practice for the Pacific Southwest from November 1995 to May 2002. Ms. Provencio is currently a member of the Board of Regents of Loyola Marymount University and on the board of Beazer Homes (chair of audit committee and member of compensation committee). In addition, Ms. Provencio is a former director of VPI, International Aluminum Corporation and Signalife, Inc.

Lloyd Segal

Mr. Lloyd M. Segal is Independent Director of Valeant Pharmaceuticals International Inc., since December 2007. Since February 2010, Mr. Segal has been a General Partner at Persistence Capital Partners, a healthcare focused private equity fund. From 1998 to 2008, he served as President and CEO of Caprion Pharmaceuticals which became Thallion Pharmaceuticals, Inc. in 2007, where he still serves as chairman of the board. He was previously a management consultant with McKinsey and President and CEO of Advanced Bioconcept Ltd. Mr. Segal currently serves on the board of Thallion Pharmaceuticals, Inc. and GBC American Growth Fund, Inc. and on the Advisory Council of the School of Science at Brandeis University.

Katharine Stevenson

Ms. Katharine B. Stevenson is Independent Director of Valeant Pharmaceuticals International Inc., since September 2010. Ms. Stevenson is a Corporate Director who serves on a variety of corporate and not-for-profit boards. She was formerly a senior executive of Nortel from 1995-2007 and has over 20 years of experience as a senior financial executive in Canada and the United States. Ms. Stevenson was responsible for all treasury activity at Nortel, including global treasury operations, corporate and structured finance, credit, and risk management. Prior to joining Nortel, Ms. Stevenson held various progressively senior finance roles at J.P. Morgan & Company, Inc. She was with J.P. Morgan from 1984 to 1995. Ms. Stevenson is currently a member of the board of directors of CAE Inc. (member of audit committee), Open Text Corporation (member of audit committee) and the Canadian Imperial Bank of Commerce (member of risk management committee). She formerly was a director of Afexa Life Sciences, Inc. and OSI Pharmaceuticals Inc. Ms. Stevenson is also a past Chair and Governor of The Bishop Strachan School and a Vice Chair and Governor of the University of Guelph. She has received her ICD.D, the professional designation for directors in Canada.

Laurie Little

Search Stocks